Alzheimer Disease Biomarkers in Clinical Practice: A Blood-Based Diagnostic Revolution

An estimated 6.1 million Americans live with cognitive impairment—a number that is expected to triple by 2050. Alzheimer disease (AD) is the most common cause of impairment. The development of blood-based biomarkers capable of detecting pathological changes of AD in living patients has the potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Paczynski, Madeline M., Day, Gregory S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742698/
https://www.ncbi.nlm.nih.gov/pubmed/36475976
http://dx.doi.org/10.1177/21501319221141178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742698/
https://www.ncbi.nlm.nih.gov/pubmed/36475976
http://dx.doi.org/10.1177/21501319221141178

Ejemplares similares